Navigation Links
New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
Date:9/21/2011

011 and at a BI-sponsored symposium on Monday, Sept. 26, 2011. Key presentations include:

  • Efficacy of BIBF 1120 in patients with IPF is dose-dependent: results from the TOMORROW trial (Sunday, Sept. 25, 2011, 8:30-8:45 a.m. CEST)
  • Effect of baseline FVC on preservation of lung function with BIBF 1120: results from the TOMORROW trial (Sunday, Sept. 25, 2011, 8:45-9 a.m. CEST)
  • Presentation of the NEJM TOMORROW paper; Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis at the ERS/NEJM "Late Breaking Research Session" (Monday, Sept. 26, 2011, 1:18-1:36 p.m. CEST)
  • Satellite symposium: Idiopathic Pulmonary Fibrosis: Evolutions in Diagnosis and Treatment  (Monday, Sept. 26, 2011, 5:15-7:15 p.m. CEST)

About the TOMORROW Trial

The phase II TOMORROW trial was a 12-month, randomized, double-blind, placebo-controlled trial conducted at 92 sites in 25 countries. The trial evaluated the safety and efficacy of oral BIBF 1120 at four dosage levels in reducing decline in lung function measured by FVC among 432 patients diagnosed with IPF, as defined by the American Thoracic Society (ATS) and ERS.

The primary endpoint for the TOMORROW trial was annual rate of decline in FVC. Secondary endpoints included acute exacerbations, quality of life using the SGRQ and total lung capacity.

About BIBF 1120

BIBF 1120 is an investigational small molecule tyrosine kinase inhibitor (TKI) in development by Boehringer Ingelheim for idiopathic pulmonary fibrosis (IPF). It targets three growth factors: the vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR). These receptors have been shown to be potentially involved in pathomechanisms of pulmonary fibrosis. By blocking these signaling pathways that are inv
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Lung Cancer Study Reveals Similar Outcomes for African-American and Caucasian Patients Treated With Alimta®
2. Studying Fluid Overflow in Patients With Devices
3. Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment
4. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
5. Data From QNEXA Sequel Study Featured at the 47th EASD Annual Meeting
6. The 62nd Annual Meeting of the American Association for the Study of Liver Diseases
7. Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
8. First Patient Enrolled in SARcode Biosciences Pivotal Dry Eye Study of SAR 1118 Ophthalmic Solution
9. Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
10. Breast Health Study Advances Safety Profile for Soy-Based Natural S-equol Supplement Designed to Manage Menopause Symptoms
11. Neurocrine Biosciences Announces the Start of Phase II Study of Elagolix in Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015 Gem Pharmaceuticals announced today that the initial ... the Company,s Phase 2 clinical trial.  This open-label study ... compound, GPX-150 (an investigational medication), in approximately 30 adults ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... a privately held medical device company, announced today that ... ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) to sell ... cancer in Japan . ViewRay,s technology, ... only MRI-guided radiation therapy system that images and treats ...
(Date:1/22/2015)... Jan. 22, 2015  ResMed Inc. (NYSE: RMD ) ... Revenue for the quarter was $423.0 million, a 10 percent ... 14 percent increase on a constant currency basis). Net income ... the quarter ended December 31, 2013. Diluted earnings per share ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11
... London, UK, June 11, 2007-ReGen is pleased to ... on Colostrinin, its,nutraceutical product which the Company believes ... presented today at the,2007 International Congress on Natural ... Kruzel, ReGen's Chief,Scientific Officer. , The conference, which ...
... Norway, 11 June 2007 - Clavis Pharma (OSE: ... clinical Phase I/II,study with ELACYT in hematologic cancers ... the European Hematology Association (EHA) in,Vienna. ELACYT is ... of hematologic cancers as well as for solid ...
Cached Medicine Technology:Data Showing that ReGen's Colostrinin Supports Healthy Cognitive,Function Presented at the 2007 International Congress on Natural,Medicine in Australia 2Clavis Pharma Presented Preliminary Clinical Data on Elacyt at EHA 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 The federal court ... the U.S. District Court, Southern District of West Virginia has ... in that proceeding’s first bellwether trial. In an Order dated ... new trial after finding that C.R. Bard had not proven ...
(Date:1/22/2015)... Thousand of GranuFlo lawsuits ( http://www.granuflolawsuit2014.com/ ... GranuFlo and NaturaLyte dialysis concentrates continue to move forward ... Court, District of Massachusetts, Bernstein Liebhard LLP reports. According ... remanded a case filed by the state of Louisiana ...
(Date:1/22/2015)... released a new blog post presenting the basic features of ... an accidental death and dismemberment rider for a car insurance ... benefits if the insured dies in an accident. Accidental death ... insurance. , AD&D is not expensive and can be ...
(Date:1/22/2015)... Yesterday, Senator Holly Mitchell (D-Los ... Olsen (R-Modesto) were honored by the California Healthcare ... biomedical science, medical device and pharmaceutical innovation in ... “2014 Life Sciences Champion” award from CHI President ...
(Date:1/22/2015)... years since the release of their debut recording Love is King, ... & Matthew Love – the duo are pleased to announce their ... Swan Records on February 24, 2015. , THE ROAD offers the ... all of us to walk out of the mire of our ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... VIEW, Calif., March 4 Based on ... biotechnology market, Frost & Sullivan presents OVATION ... Frost & Sullivan Award for Entrepreneurial Company ... company,s success in achieving its growth objectives ...
... 4 Cardiogenesis Corporation (Pink Sheets: CGCP), announced that ... and full year ended December 31, 2008 prior to ... company also said that President Richard P. Lanigan and ... Abbott will host an investor conference call that day ...
... NVC-422 Demonstrates Ability to Treat Subcutaneous InfectionsEMERYVILLE, Calif., ... NBY), a clinical stage biopharmaceutical company, today announced ... lead molecule in NovaBay,s, proprietary Aganocide(R) class of ... of Dermatology (AAD) 67th Annual Meeting in San ...
... ,Smart, house for people with dementia are just ... on 4th March, organised by the Engineering and ... is a free event aiming to bring together, ... business people. The event includes a dynamic, interactive ...
... Long Looked For Ways To Whiten Teeth In The Comfort Of Their Own ... As In The Dentist Office. A New Teeth Whitening Product, Hollywood Sexy Smile, ... Same Results Without The Costs and Hassles Of Going To The Dentist Office. ... ...
... drugs and endocrine-disrupting compounds found in our public drinking water are ... report by the Water Research Foundation, the nation,s leading drinking water ... ... 2009 -- The concentrations of pharmaceutical drugs and endocrine-disrupting compounds found ...
Cached Medicine News:Health News:Frost & Sullivan Lauds OVATION Pharmaceuticals for Its Business Model and Ability to Sustain Growth 2Health News:Frost & Sullivan Lauds OVATION Pharmaceuticals for Its Business Model and Ability to Sustain Growth 3Health News:Frost & Sullivan Lauds OVATION Pharmaceuticals for Its Business Model and Ability to Sustain Growth 4Health News:Cardiogenesis Corporation to Report 2008 Fourth Quarter and Year-End Results on March 31st 2Health News:NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67th Annual Meeting 2Health News:NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67th Annual Meeting 3Health News:Daisyphone, virtual cocoon and smart house at London science conference 2Health News:Teeth Whitening Ranks Most Desired Cosmetic Procedure For Women. Hollywood Sexy Smile Whitens Teeth At Home 8 Shades Without The Dentist. 2Health News:Levels of Trace Pharmaceuticals in Drinking Water Too Low to Impact Human Health According to Water Research Foundation Study 2Health News:Levels of Trace Pharmaceuticals in Drinking Water Too Low to Impact Human Health According to Water Research Foundation Study 3Health News:Levels of Trace Pharmaceuticals in Drinking Water Too Low to Impact Human Health According to Water Research Foundation Study 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: